Gene associations
This page shows the different gene sets that are used in LIDPD. External resources such as Entrez, dbSNP, or Pubmed are referenced from the table. You can find all networks for a particular gene by clicking on the respective Search link in the first column. All tables can be sorted by clicking on a particular column name.
Panel: LID contains 20 genes and 25 single nucleotide polymorphisms associated with Levodopa-induced dyskinesia that we curated from the literature. The different Highlight datasets contain additional gene annotations, e.g., associations with Parkinson's disease (PDRelated, PDCandidate, and PDGWAS contain PD associations with decreasing evidence levels), drug targets (DrugApproved), or Gene Ontology annotations (GOslimPD describes Parkinson's disease associated processes, GOslimNeuro neurotransmitter-associated processes).
Please note that while the Panel table lists all genes of the datasets, the highlight tables only show those genes that are present in at least one network, with a maximum of 200 entries. As a result, you might encounter empty highlight sets. To explore the full set you have to download the data archive. Please contact us if you think that we missed an association or if you spotted an error in the data.
Click here to search for all sets and networks involving any of the 20 genes of this set.
| Search | Entrez Gene ID | HGNC symbol | dbSNP ID | Publication | PMID | Annotator comment | |
|---|---|---|---|---|---|---|---|
| Search | 135 | ADORA2A | rs2298383 | Rieck et al. 2015 | 25872644 | -- | |
| Search | 135 | ADORA2A | rs3761422 | Rieck et al. 2015 | 25872644 | -- | |
| Search | 255239 | ANKK1 | rs1800497 | Rieck et al. 2012 | 23171335 | -- | |
| Search | 255239 | ANKK1 | rs2734849 | Rieck et al. 2012 | 23171335 | — | |
| Search | 627 | BDNF | rs6265 | Foltynie et al. 2009 | 18977816 | -- | |
| Search | 627 | BDNF | rs6265 | Kusters et al. 2018 | 29191473 | Variant individually associated | |
| Search | 1312 | COMT | rs4680 | Bialecka et al. 2004 | 15355491 | -- | |
| Search | 1312 | COMT | rs4680 | Hao et al. 2014 | 25034874 | -- | |
| Search | 1312 | COMT | rs4680 | Cheshire al. 2014 | 24008922 | -- | |
| Search | 1312 | COMT | rs4680 | de Lau et al. 2011 | 22083803 | -- | |
| Search | 1813 | DRD2 | - | Oliveri et al. 1999 | 10534246 | -- | |
| Search | 1813 | DRD2 | - | Zappia et al. 2005 | 15824260 | -- | |
| Search | 1813 | DRD2 | - | Strong et al. 2006 | 16435402 | -- | |
| Search | 1813 | DRD2 | rs2283265 | Rieck et al. 2012 | 23171335 | -- | |
| Search | 1813 | DRD2 | rs1076560 | Rieck et al. 2012 | 23171335 | -- | |
| Search | 1813 | DRD2 | rs6277 | Rieck et al. 2012 | 23171335 | -- | |
| Search | 1814 | DRD3 | rs6280 | Lee et al. 2011 | 20945430 | -- | |
| Search | 1979 | EIF4EBP2 | rs1043098 | Martin-Flores et al. 2018 | 29992529 | Variant individually associated | |
| Search | 89848 | FCHSD1 | rs456998 | Martin-Flores et al. 2018 | 29992529 | Variant not individually associated | |
| Search | 9456 | HOMER1 | rs4704559 | Schumacher-Schuh et al. 2014 | 24126708 | -- | |
| Search | 3265 | HRAS | rs12628 | Martin-Flores et al. 2018 | 29992529 | Variant individually associated | |
| Search | 120892 | LRRK2 | rs34637584 | Lesage et al. 2008 | 18981379 | -- | |
| Search | 120892 | LRRK2 | rs34637584 | Healy et al. 2008 PMID: | 18539534 | -- | |
| Search | 4128 | MAOA | rs6323 | Cheshire al. 2014 | 24008922 | -- | |
| Search | 4129 | MAOB | - | Bialecka et al. 2004 | 15355491 | -- | |
| Search | 4129 | MAOB | rs1799836 | Hao et al. 2014 | 25034874 | -- | |
| Search | 4988 | OPRM1 | rs1799971 | Strong et al. 2006 | 16435402 | -- | |
| Search | 5578 | PRKCA | rs4790904 | Martin-Flores et al. 2018 | 29992529 | Variant not individually associated | |
| Search | 5071 | PRKN | rs1801582 | Martin-Flores et al. 2018 | 29992529 | Variant individually associated | |
| Search | 253260 | RICTOR | rs2043112 | Martin-Flores et al. 2018 | 29992529 | Variant not individually associated | |
| Search | 6196 | RPS6KA2 | rs6456121 | Martin-Flores et al. 2018 | 29992529 | Variant not individually associated | |
| Search | 6198 | RPS6KB1 | rs1292034 | Martin-Flores et al. 2018 | 29992529 | Variant not individually associated | |
| Search | 6531 | SLC6A3 | - | Kaiser et al. 2003 | 12796525 | -- | |
| Search | 6531 | SLC6A3 | rs393795 | Kaplan et al. 2014 | 24633632 | -- | |
| Search | 6531 | SLC6A3 | rs393795 | Purcaro et al. 2018 | 30316985 | Variant not individually associated | |
| Search | 6531 | SLC6A3 | rs28363170 | Purcaro et al. 2018 | 30316985 | Variant not individually associated | |
| Search | 6531 | SLC6A3 | rs28363170 | DosSantos et al. 2018 | 30353564 | Variant individually associated |
Click here to search for all sets and networks involving any of the 130 genes of this set.
| Search | Entrez Gene ID | HGNC Symbol | UniProtKB Acc | Drugbank ID | Drug name | Known action | Actions | Type | Groups | Description |
|---|---|---|---|---|---|---|---|---|---|---|
| Search | 2692 | GHRHR | Q02643 | DB00010 | Sermorelin | yes | agonist | biotech | approved, withdrawn | Sermorelin acetate is the acetate salt of an amidated synthetic 29-amino acid peptide (GRF 1-29 NH 2 ) that corresponds to the amino-terminal segment of the naturally occurring human growth hormone-releasing hormone (GHRH or GRF) consisting of 44 amino acid residues |
| Search | 1312 | COMT | P21964 | DB00323 | Tolcapone | yes | inhibitor | small molecule | approved, withdrawn | Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity. [Wikipedia] |
| Search | 1813 | DRD2 | P14416 | DB00409 | Remoxipride | yes | antagonist | small molecule | approved, withdrawn | An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem] |
| Search | 1814 | DRD3 | P35462 | DB00409 | Remoxipride | unknown | antagonist | small molecule | approved, withdrawn | An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem] |
| Search | 1815 | DRD4 | P21917 | DB00409 | Remoxipride | unknown | antagonist | small molecule | approved, withdrawn | An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia. [PubChem] |
| Search | 153 | ADRB1 | P08588 | DB00866 | Alprenolol | yes | antagonist | small molecule | approved, withdrawn | One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. |
| Search | 3350 | HTR1A | P08908 | DB00866 | Alprenolol | yes | antagonist | small molecule | approved, withdrawn | One of the adrenergic beta-antagonists used as an antihypertensive, anti-anginal, and anti-arrhythmic agent. Alprenolol is no longer marketed by AstraZeneca, but may still be available in generic varieties. |
| Search | 1813 | DRD2 | P14416 | DB00875 | Flupentixol | yes | antagonist | small molecule | approved, withdrawn | Flupentixol is an antipsychotic neuroleptic drug. It is a thioxanthene, and therefore closely related to the phenothiazines. Its primary use is as a long acting injection given two or three weekly to people with schizophrenia who have a poor compliance with medication and suffer frequent relapses of illness. It is a D1 and D2 receptor antagonist. It is not approved in the United States. |
| Search | 6531 | SLC6A3 | Q01959 | DB01149 | Nefazodone | unknown | inhibitor | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 3350 | HTR1A | P08908 | DB01149 | Nefazodone | yes | antagonist | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 150 | ADRA2A | P08913 | DB01149 | Nefazodone | unknown | antagonist | small molecule | approved, withdrawn | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury, which could lead to the need for a liver transplant, or even death. The incidence of severe liver damage is approximately 1 in 250,000 to 300,000 patient-years. On May 20, 2004, Bristol-Myers Squibb discontinued the sale of Serzone in the United States. [Wikipedia] |
| Search | 1129 | CHRM2 | P08172 | DB01231 | Diphenidol | yes | antagonist | small molecule | approved, withdrawn | Diphenidol is an antiemetic agent used in the treatment of vomiting and vertigo. Diphenidol overdose may result in serious toxicity in children. |
| Search | 1813 | DRD2 | P14416 | DB01239 | Chlorprothixene | yes | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 1129 | CHRM2 | P08172 | DB01239 | Chlorprothixene | no | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 1814 | DRD3 | P35462 | DB01239 | Chlorprothixene | yes | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 1132 | CHRM4 | P08173 | DB01239 | Chlorprothixene | no | antagonist | small molecule | approved, withdrawn | Chlorprothixene is a typical antipsychotic drug of the thioxanthene (tricyclic) class. Chlorprothixene exerts strong blocking effects by blocking the 5-HT2 D1, D2, D3, histamine H1, muscarinic and alpha1 adrenergic receptors. |
| Search | 801 | CALM1 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 801 | CALM2 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 801 | CALM3 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 805 | CALM1 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 805 | CALM2 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 805 | CALM3 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 808 | CALM1 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 808 | CALM2 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 808 | CALM3 | P62158 | DB01244 | Bepridil | unknown | binder | small molecule | approved, withdrawn | \\A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). |
| Search | 1813 | DRD2 | P14416 | DB06144 | Sertindole | yes | antagonist | small molecule | approved, withdrawn | Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market. |
| Search | 3362 | HTR6 | P50406 | DB06144 | Sertindole | yes | antagonist | small molecule | approved, withdrawn | Sertindole, a neuroleptic, is one of the newer antipsychotic medications available. Serdolect is developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative. It was first marketed in 1996 in several European countries before being withdrawn two years later because of numerous cardiac adverse effects. It has once again been approved and should soon be available on the French and Australian market. |
| Search | 2904 | GRIN2B | Q13224 | DB08954 | Ifenprodil | yes | antagonist | small molecule | approved, withdrawn | Ifenprodil is a selective NMDA receptor (glutamate) antagonist. |
| Search | 153 | ADRB1 | P08588 | DB00397 | Phenylpropanolamine | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Phenylpropanolamine has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug. |
| Search | 150 | ADRA2A | P08913 | DB00397 | Phenylpropanolamine | yes | agonist | small molecule | approved, vet_approved, withdrawn | Phenylpropanolamine has been withdrawn in Canada and the United States. In November 2000, the Food and Drug Administration (FDA) issued a public health advisory against the use of the drug. |
| Search | 1813 | DRD2 | P14416 | DB01186 | Pergolide | yes | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3352 | HTR1D | P28221 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3351 | HTR1B | P28222 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 3350 | HTR1A | P08908 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 1816 | DRD5 | P21918 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 1814 | DRD3 | P35462 | DB01186 | Pergolide | yes | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 1815 | DRD4 | P21917 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 150 | ADRA2A | P08913 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 151 | ADRA2B | P18089 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 152 | ADRA2C | P18825 | DB01186 | Pergolide | unknown | agonist | small molecule | approved, vet_approved, withdrawn | Pergolide is a long-acting dopamine agonist approved in 1982 for the treatment of ParkinsonÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s Disease. It is an ergot derivative that acts on the dopamine D2 and D3, alpha2- and alpha1-adrenergic, and 5-hydroxytryptamine (5-HT) receptors. It was indicated as adjunct therapy with levodopa/carbidopa in the symptomatic treatment of parkinsonian syndrome. It was later found that pergolide increased the risk of cardiac valvulopathy. The drug was withdrawn from the US market in March 2007 and from the Canadian market in August 2007. |
| Search | 7253 | TSHR | P16473 | DB00024 | Thyrotropin Alfa | yes | agonist | biotech | approved, vet_approved | Thyrotropin alfa is a recombinant form of thyroid stimulating hormone used in performing certain tests in patients who have or have had thyroid cancer. It is also used along with a radioactive agent to destroy remaining thyroid tissue in certain patients who have had their thyroid gland removed because of thyroid cancer. It is a heterodimeric glycoprotein comprised of two non-covalently linked subunits, an alpha subunit of 92 amino acid residues containing two N-linked glycosylation sites and a beta subunit of 112 residues containing one N-linked glycosylation site. The alpha subunit is nearly identical to that of human chorionic gonadotropin (hCG), luteinizing hormone (LH), and follicle-stimulating hormone (FSH). The alpha subunit is thought to be the effector region responsible for stimulation of adenylate cyclase (involved the generation of cAMP). The beta subunit (TSHB) is unique to TSH, and therefore determines its receptor specificity. The amino acid sequence of thyrotropin alfa is identical to that of human pituitary thyroid stimulating hormone. |
| Search | 2492 | FSHR | P23945 | DB00094 | Urofollitropin | yes | agonist | biotech | approved, vet_approved | Urofollitropin is a purified form of follicle-stimulating hormone (FSH) that is manufactured by extraction from human urine and then purified. It consists of two non-covalently linked, non-identical glycoproteins designated as the alpha- and beta- subunits. The alpha- and beta- subunits have 92 and 111 amino acids. The alpha subunit is glycosylated at Asn 51 and Asn 78 while the beta subunit is glycosylated at Asn 7 and Asn 24. Urofollitropin is important in the development of follicles produced by the ovaries. Given by subcutaneous injection, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. Urofollitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF). |
| Search | 2890 | GRIA1 | P42261 | DB00228 | Enflurane | yes | antagonist | small molecule | approved, vet_approved | An extremely stable inhalation anesthetic that allows rapid adjustments of anesthesia depth with little change in pulse or respiratory rate. [PubChem] |
| Search | 4986 | OPRK1 | P41145 | DB00396 | Progesterone | unknown | activator | small molecule | approved, vet_approved | The major progestational steroid that is secreted primarily by the corpus luteum and the placenta. Progesterone acts on the uterus, the mammary glands, and the brain. It is required in embryo implantation, pregnancy maintenance, and the development of mammary tissue for milk production. Progesterone, converted from pregnenolone, also serves as an intermediate in the biosynthesis of gonadal steroid hormones and adrenal corticosteroids. [PubChem] |
| Search | 1813 | DRD2 | P14416 | DB00420 | Promazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1129 | CHRM2 | P08172 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1815 | DRD4 | P21917 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1132 | CHRM4 | P08173 | DB00420 | Promazine | unknown | antagonist | small molecule | approved, vet_approved | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States. |
| Search | 1813 | DRD2 | P14416 | DB00433 | Prochlorperazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine antipsychotic used principally in the treatment of nausea; vomiting; and vertigo. It is more likely than chlorpromazine to cause extrapyramidal disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612) |
| Search | 1813 | DRD2 | P14416 | DB00450 | Droperidol | yes | antagonist | small molecule | approved, vet_approved | A butyrophenone with general properties similar to those of haloperidol. It is used in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593) |
| Search | 1813 | DRD2 | P14416 | DB00477 | Chlorpromazine | yes | antagonist | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 3350 | HTR1A | P08908 | DB00477 | Chlorpromazine | yes | antagonist | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 3363 | HTR7 | P34969 | DB00477 | Chlorpromazine | unknown | binder | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 1816 | DRD5 | P21918 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 1814 | DRD3 | P35462 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 1815 | DRD4 | P21917 | DB00477 | Chlorpromazine | unknown | binder | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 3362 | HTR6 | P50406 | DB00477 | Chlorpromazine | unknown | binder | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 59340 | HRH4 | Q9H3N8 | DB00477 | Chlorpromazine | unknown | binder | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] |
| Search | 801 | CALM1 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 801 | CALM2 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 801 | CALM3 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 805 | CALM1 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 805 | CALM2 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 805 | CALM3 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 808 | CALM1 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 808 | CALM2 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 808 | CALM3 | P62158 | DB00477 | Chlorpromazine | unknown | small molecule | approved, vet_approved | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. [PubChem] | |
| Search | 1813 | DRD2 | P14416 | DB00508 | Triflupromazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem] |
| Search | 1129 | CHRM2 | P08172 | DB00508 | Triflupromazine | yes | antagonist | small molecule | approved, vet_approved | A phenothiazine used as an antipsychotic agent and as an antiemetic. [PubChem] |
| Search | 7846 | TUBA1A | Q71U36 | DB00518 | Albendazole | no | inhibitor | small molecule | approved, vet_approved | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) |
| Search | 801 | CALM1 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 801 | CALM2 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 801 | CALM3 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 805 | CALM1 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 805 | CALM2 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 805 | CALM3 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 808 | CALM1 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 808 | CALM2 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 808 | CALM3 | P62158 | DB00527 | Cinchocaine | unknown | inhibitor | small molecule | approved, vet_approved | A local anesthetic of the amide type now generally used for surface anesthesia. It is one of the most potent and toxic of the long-acting local anesthetics and its parenteral use is restricted to spinal anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1006) |
| Search | 1129 | CHRM2 | P08172 | DB00572 | Atropine | yes | antagonist | small molecule | approved, vet_approved | An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae. [PubChem] |
| Search | 1132 | CHRM4 | P08173 | DB00572 | Atropine | yes | antagonist | small molecule | approved, vet_approved | An alkaloid, originally from Atropa belladonna, but found in other plants, mainly solanaceae. [PubChem] |
| Search | 150 | ADRA2A | P08913 | DB00633 | Dexmedetomidine | yes | agonist | small molecule | approved, vet_approved | An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem] |
| Search | 7846 | TUBA1A | Q71U36 | DB00643 | Mebendazole | yes | inhibitor | small molecule | approved, vet_approved | A benzimidazole that acts by interfering with carbohydrate metabolism and inhibiting polymerization of microtubules. [PubChem] |
| Search | 4988 | OPRM1 | P35372 | DB00652 | Pentazocine | yes | antagonist | small molecule | approved, vet_approved | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) |
| Search | 4986 | OPRK1 | P41145 | DB00652 | Pentazocine | yes | agonist | small molecule | approved, vet_approved | The first mixed agonist-antagonist analgesic to be marketed. It is an agonist at the kappa and sigma opioid receptors and has a weak antagonist action at the mu receptor. (From AMA Drug Evaluations Annual, 1991, p97) |
| Search | 153 | ADRB1 | P08588 | DB00668 | Epinephrine | yes | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 150 | ADRA2A | P08913 | DB00668 | Epinephrine | yes | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 151 | ADRA2B | P18089 | DB00668 | Epinephrine | yes | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 152 | ADRA2C | P18825 | DB00668 | Epinephrine | unknown | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 155 | ADRB3 | P13945 | DB00668 | Epinephrine | unknown | agonist | small molecule | approved, vet_approved | The active sympathomimetic hormone from the adrenal medulla in most species. It stimulates both the alpha- and beta- adrenergic systems, causes systemic vasoconstriction and gastrointestinal relaxation, stimulates the heart, and dilates bronchi and cerebral vessels. It is used in asthma and cardiac failure and to delay absorption of local anesthetics. [PubChem] |
| Search | 2890 | GRIA1 | P42261 | DB00753 | Isoflurane | yes | antagonist | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 801 | CALM1 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 801 | CALM2 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 801 | CALM3 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 805 | CALM1 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 805 | CALM2 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 805 | CALM3 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 808 | CALM1 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 808 | CALM2 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 808 | CALM3 | P62158 | DB00753 | Isoflurane | unknown | other/unknown | small molecule | approved, vet_approved | A stable, non-explosive inhalation anesthetic, relatively free from significant side effects. [PubChem] |
| Search | 150 | ADRA2A | P08913 | DB00797 | Tolazoline | unknown | antagonist | small molecule | approved, vet_approved | A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem] |
| Search | 151 | ADRA2B | P18089 | DB00797 | Tolazoline | unknown | binder | small molecule | approved, vet_approved | A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem] |
| Search | 152 | ADRA2C | P18825 | DB00797 | Tolazoline | unknown | binder | small molecule | approved, vet_approved | A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem] |
| Search | 3274 | HRH2 | P25021 | DB00797 | Tolazoline | unknown | agonist | small molecule | approved, vet_approved | A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn. [PubChem] |
| Search | 7157 | TP53 | P04637 | DB00945 | Acetylsalicylic acid | unknown | acetylation | small molecule | approved, vet_approved | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) |
| Search | 6197 | RPS6KA3 | P51812 | DB00945 | Acetylsalicylic acid | unknown | small molecule | approved, vet_approved | The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Acetylsalicylic acid also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) | |
| Search | 153 | ADRB1 | P08588 | DB01001 | Salbutamol | unknown | agonist | small molecule | approved, vet_approved | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma. |
| Search | 2890 | GRIA1 | P42261 | DB01028 | Methoxyflurane | yes | antagonist | small molecule | approved, vet_approved | An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) |
| Search | 54331 | GNG2 | P59768 | DB01159 | Halothane | unknown | other/unknown | small molecule | approved, vet_approved | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) |
| Search | 5739 | PTGIR | P43119 | DB01160 | Dinoprost Tromethamine | unknown | antagonist | small molecule | approved, vet_approved | The tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine. |
| Search | 1385 | CREB1 | P16220 | DB01183 | Naloxone | no | other/unknown | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 4988 | OPRM1 | P35372 | DB01183 | Naloxone | yes | antagonist | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 4986 | OPRK1 | P41145 | DB01183 | Naloxone | yes | antagonist | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 4985 | OPRD1 | P41143 | DB01183 | Naloxone | yes | antagonist | small molecule | approved, vet_approved | A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors. |
| Search | 1813 | DRD2 | P14416 | DB01221 | Ketamine | unknown | agonist|partial agonist | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 4988 | OPRM1 | P35372 | DB01221 | Ketamine | unknown | binder | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 4986 | OPRK1 | P41145 | DB01221 | Ketamine | unknown | agonist | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 4985 | OPRD1 | P41143 | DB01221 | Ketamine | unknown | binder | small molecule | approved, vet_approved | A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (receptors, N-methyl-D-aspartate) and may interact with sigma receptors. [PubChem] |
| Search | 81027 | TUBB1 | Q9H4B7 | DB01229 | Paclitaxel | yes | inhibitor | small molecule | approved, vet_approved | \\Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. |
| Search | 596 | BCL2 | P10415 | DB01229 | Paclitaxel | yes | inhibitor | small molecule | approved, vet_approved | \\Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. |
| Search | 4137 | MAPT | P10636 | DB01229 | Paclitaxel | yes | small molecule | approved, vet_approved | \\Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a US National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it taxol. Later it was discovered that endophytic fungi in the bark synthesize paclitaxel. | |
| Search | 2890 | GRIA1 | P42261 | DB01236 | Sevoflurane | yes | antagonist | small molecule | approved, vet_approved | Sevoflurane (2,2,2-trifluoro-1-[trifluoromethyl]ethyl fluoromethyl ether), also called fluoromethyl, is a sweet-smelling, non-flammable, highly fluorinated methyl isopropyl ether used for induction and maintenance of general anesthesia. Together with desflurane, it is replacing isoflurane and halothane in modern anesthesiology. [Wikipedia] |
| Search | 4158 | MC2R | Q01718 | DB01285 | Corticotropin | yes | agonist | biotech | approved, vet_approved | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. |
| Search | 1392 | CRH | P06850 | DB01285 | Corticotropin | unknown | agonist | biotech | approved, vet_approved | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. |
| Search | 1813 | DRD2 | P14416 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3352 | HTR1D | P28221 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3351 | HTR1B | P28222 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 3350 | HTR1A | P08908 | DB01392 | Yohimbine | unknown | partial agonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 1814 | DRD3 | P35462 | DB01392 | Yohimbine | unknown | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 150 | ADRA2A | P08913 | DB01392 | Yohimbine | yes | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 151 | ADRA2B | P18089 | DB01392 | Yohimbine | yes | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 152 | ADRA2C | P18825 | DB01392 | Yohimbine | yes | antagonist | small molecule | approved, vet_approved | A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac. [PubChem] |
| Search | 153 | ADRB1 | P08588 | DB01407 | Clenbuterol | unknown | agonist | small molecule | approved, vet_approved | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [PubChem] |
| Search | 155 | ADRB3 | P13945 | DB01407 | Clenbuterol | unknown | agonist | small molecule | approved, vet_approved | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [PubChem] |
| Search | 4803 | NGF | P01138 | DB01407 | Clenbuterol | unknown | stimulator | small molecule | approved, vet_approved | A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma. [PubChem] |
| Search | 1813 | DRD2 | P14416 | DB01614 | Acepromazine | yes | antagonist | small molecule | approved, vet_approved | Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. |
| Search | 3350 | HTR1A | P08908 | DB01614 | Acepromazine | yes | antagonist | small molecule | approved, vet_approved | Acepromazine is one of the phenothiazine derivative psychotropic drugs, used little in humans, however frequently in animals as a sedative and antiemetic. |
| Search | 1132 | CHRM4 | P08173 | DB01625 | Isopropamide | unknown | antagonist | small molecule | approved, vet_approved | Isopropamide iodide is a long-acting quaternary anticholinergic drug. It is used in the treatment of peptic ulcer and other gastrointestinal disorders marked by hyperacidity and hypermotility. |
| Search | 708 | C1QBP | Q07021 | DB08818 | Hyaluronic acid | unknown | binder | small molecule | approved, vet_approved | Hyaluronic acid (HA) is an anionic, nonsulfated glycosaminoglycan distributed widely throughout connective, epithelial, and neural tissues. It is unique among glycosaminoglycans in that it is nonsulfated, forms in the plasma membrane instead of the Golgi, and can be very large, with its molecular weight often reaching the millions. One of the chief components of the extracellular matrix, hyaluronic acid contributes significantly to cell proliferation and migration, and may also be involved in the progression of some malignant tumors. |
| Search | 3973 | LHCGR | P22888 | DB09126 | Chorionic Gonadotropin (Human) | yes | ligand | biotech | approved, vet_approved | \\Human chorionic gonadotropin (HCG), a polypeptide hormone produced by the human placenta. Endogenously produced HCG interacts with the LHCG receptor of the ovary and promotes the maintenance of the corpus luteum during the beginning of pregnancy. This allows the corpus luteum to continuously secrete the hormone progesterone during the first trimester, which is required for maintenance of the uterus and prevents menstruation. In males, HCG also stimulates the production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens. |
| Search | 4128 | MAOA | P21397 | DB01363 | Ephedra | yes | inhibitor | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 6531 | SLC6A3 | Q01959 | DB01363 | Ephedra | yes | negative modulator | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 4129 | MAOB | P27338 | DB01363 | Ephedra | yes | inhibitor | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 153 | ADRB1 | P08588 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 150 | ADRA2A | P08913 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 151 | ADRA2B | P18089 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 152 | ADRA2C | P18825 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 155 | ADRB3 | P13945 | DB01363 | Ephedra | yes | agonist | small molecule | approved, nutraceutical, withdrawn | Ephedra is an alkaloid chemical compound traditionally obtained from the plant Ephedra sinica. The sale of ephedra-containing supplements was banned in the United States in 2004. The drug is still sold in Canada in OTC formulations. |
| Search | 2841 | GPR18 | Q14330 | DB00145 | Glycine | unknown | small molecule | approved, nutraceutical, vet_approved | A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter. [PubChem] | |
| Search | 5578 | PRKCA | P17252 | DB00163 | Vitamin E | unknown | small molecule | approved, nutraceutical, vet_approved | A generic descriptor for all tocopherols and tocotrienols that exhibit alpha-tocopherol activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of isoprenoids. [PubChem] | |
| Search | 5579 | PRKCB | P05771 | DB00163 | Vitamin E | unknown | small molecule | approved, nutraceutical, vet_approved | A generic descriptor for all tocopherols and tocotrienols that exhibit alpha-tocopherol activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of isoprenoids. [PubChem] | |
| Search | 5515 | PPP2CA | P67775 | DB00163 | Vitamin E | unknown | small molecule | approved, nutraceutical, vet_approved | A generic descriptor for all tocopherols and tocotrienols that exhibit alpha-tocopherol activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of isoprenoids. [PubChem] | |
| Search | 801 | CALM1 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 801 | CALM2 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 801 | CALM3 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 805 | CALM1 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 805 | CALM2 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 805 | CALM3 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 808 | CALM1 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 808 | CALM2 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 808 | CALM3 | P62158 | DB01065 | Melatonin | unknown | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. | |
| Search | 4543 | MTNR1A | P48039 | DB01065 | Melatonin | yes | agonist | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. |
| Search | 4544 | MTNR1B | P49286 | DB01065 | Melatonin | yes | agonist | small molecule | approved, nutraceutical, vet_approved | Melatonin is a biogenic amine that is found in animals, plants and microbes. Aaron B. Lerner of Yale University is credited for naming the hormone and for defining its chemical structure in 1958. In mammals, melatonin is produced by the pineal gland. The pineal gland is small endocrine gland, about the size of a rice grain and shaped like a pine cone (hence the name), that is located in the center of the brain (rostro-dorsal to the superior colliculus) but outside the blood-brain barrier. The secretion of melatonin increases in darkness and decreases during exposure to light, thereby regulating the circadian rhythms of several biological functions, including the sleep-wake cycle. In particular, melatonin regulates the sleep-wake cycle by chemically causing drowsiness and lowering the body temperature. Melatonin is also implicated in the regulation of mood, learning and memory, immune activity, dreaming, fertility and reproduction. Melatonin is also an effective antioxidant. Most of the actions of melatonin are mediated through the binding and activation of melatonin receptors. Individuals with autism spectrum disorders (ASD) may have lower than normal levels of melatonin. A 2008 study found that unaffected parents of individuals with ASD also have lower melatonin levels, and that the deficits were associated with low activity of the ASMT gene, which encodes the last enzyme of melatonin synthesis. Reduced melatonin production has also been proposed as a likely factor in the significantly higher cancer rates in night workers. |
| Search | 10797 | MTHFD2 | P13995 | DB00116 | Tetrahydrofolic acid | unknown | cofactor | small molecule | approved, nutraceutical | \\Tetrahydrofolic acid is a folic acid derivative. It is produced from dihydrofolic acid by dihydrofolate reductase. |
| Search | 1312 | COMT | P21964 | DB00118 | S-Adenosylmethionine | unknown | cofactor | small molecule | approved, nutraceutical | Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed) |
| Search | 5315 | PKM | P14618 | DB00119 | Pyruvic acid | unknown | small molecule | approved, nutraceutical | An intermediate compound in the metabolism of carbohydrates, proteins, and fats. In thiamine deficiency, its oxidation is retarded and it accumulates in the tissues, especially in nervous structures. (From Stedman, 26th ed) | |
| Search | 5338 | PLD2 | O14939 | DB00122 | Choline | unknown | product of | small molecule | approved, nutraceutical | A basic constituent of lecithin that is found in many plants and animal organs. It is important as a precursor of acetylcholine, as a methyl donor in various metabolic processes, and in lipid metabolism. [PubChem] |
| Search | 1621 | DBH | P09172 | DB00126 | Vitamin C | unknown | small molecule | approved, nutraceutical | A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant. [PubChem] | |
| Search | 1385 | CREB1 | P16220 | DB00131 | Adenosine monophosphate | unknown | activator | small molecule | approved, nutraceutical | Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem] |
| Search | 107 | ADCY1 | Q08828 | DB00131 | Adenosine monophosphate | unknown | product of | small molecule | approved, nutraceutical | Adenylic acid. Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. [PubChem] |
| Search | 56670 | SUCNR1 | Q9BXA5 | DB00139 | Succinic acid | unknown | small molecule | approved, nutraceutical | A water-soluble, colorless crystal with an acid taste that is used as a chemical intermediate, in medicine, the manufacture of lacquers, and to make perfume esters. It is also used in foods as a sequestrant, buffer, and a neutralizing agent. (Hawley's Condensed Chemical Dictionary, 12th ed, p1099; McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed, p1851) | |
| Search | 5578 | PRKCA | P17252 | DB00144 | Phosphatidyl serine | unknown | small molecule | approved, nutraceutical | \\Phosphatidyl serine (PS) is a phospholipid nutrient found in fish, green leafy vegetables, soybeans and rice, and is essential for the normal functioning of neuronal cell membranes and activates Protein kinase C (PKC) which has been shown to be involved in memory function. In apoptosis, phosphatidyl serine is transferred to the outer leaflet of the plasma membrane. This is part of the process by which the cell is targeted for phagocytosis. PS has been shown to slow cognitive decline in animal models. PS has been investigated in a small number of double-blind placebo trials and has been shown to increase memory performance in the elderly. Because of the potentail cognitive benefits of phosphatidylserine, the substance is sold as a dietary supplement to people who believe they can benefit from an increased intake. | |
| Search | 107 | ADCY1 | Q08828 | DB00171 | Adenosine triphosphate | unknown | small molecule | approved, nutraceutical | An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. [PubChem] | |
| Search | 27 | ABL2 | P42684 | DB00171 | Adenosine triphosphate | unknown | inhibitor | small molecule | approved, nutraceutical | An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. [PubChem] |
| Search | 207 | AKT1 | P31749 | DB00171 | Adenosine triphosphate | unknown | small molecule | approved, nutraceutical | An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. [PubChem] | |
| Search | 156 | ADRBK1 | P25098 | DB00171 | Adenosine triphosphate | unknown | small molecule | approved, nutraceutical | An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. [PubChem] | |
| Search | 3360 | HTR4 | Q13639 | DB00604 | Cisapride | yes | agonist | small molecule | approved, investigational, withdrawn | In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias. The FDA issued a warning letter regarding this risk to health care professionals and patients. |
| Search | 4988 | OPRM1 | P35372 | DB00704 | Naltrexone | yes | antagonist | small molecule | approved, investigational, vet_approved | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. [PubChem] |
| Search | 4986 | OPRK1 | P41145 | DB00704 | Naltrexone | yes | antagonist | small molecule | approved, investigational, vet_approved | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. [PubChem] |
| Search | 4985 | OPRD1 | P41143 | DB00704 | Naltrexone | yes | antagonist | small molecule | approved, investigational, vet_approved | Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of naloxone. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence. [PubChem] |
| Search | 6531 | SLC6A3 | Q01959 | DB00721 | Procaine | yes | inhibitor | small molecule | approved, investigational, vet_approved | A local anesthetic of the ester type that has a slow onset and a short duration of action. It is mainly used for infiltration anesthesia, peripheral nerve block, and spinal block. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1016). [PubChem] |
| Search | 1129 | CHRM2 | P08172 | DB00986 | Glycopyrronium | unknown | binder | small molecule | approved, investigational, vet_approved | Glycopyrronium (as the bromide salt glycopyrrolate) is a synthetic anticholinergic agent with a quaternary ammonium structure. A muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics. In October 2015, glycopyrrolate was approved by the FDA for use as a standalone treatment for Chronic obstructive pulmonary disease (COPD), as Seebri Neohaler. |
| Search | 4128 | MAOA | P21397 | DB01037 | Selegiline | no | inhibitor | small molecule | approved, investigational, vet_approved | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. [PubChem] |
| Search | 4129 | MAOB | P27338 | DB01037 | Selegiline | yes | inhibitor | small molecule | approved, investigational, vet_approved | A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability. (From AMA Drug Evaluations Annual, 1994, p385) The compound without isomeric designation is Deprenyl. [PubChem] |
| Search | 1813 | DRD2 | P14416 | DB01184 | Domperidone | yes | antagonist | small molecule | approved, investigational, vet_approved | A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem] |
| Search | 1814 | DRD3 | P35462 | DB01184 | Domperidone | yes | antagonist | small molecule | approved, investigational, vet_approved | A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. [PubChem] |
| Search | 4988 | OPRM1 | P35372 | DB01192 | Oxymorphone | yes | agonist | small molecule | approved, investigational, vet_approved | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092) |
| Search | 4985 | OPRD1 | P41143 | DB01192 | Oxymorphone | unknown | antagonist | small molecule | approved, investigational, vet_approved | An opioid analgesic with actions and uses similar to those of morphine, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092) |
| Search | 8843 | HCAR3 | P49019 | DB00627 | Niacin | yes | agonist | small molecule | approved, investigational, nutraceutical | A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem] |
| Search | 338442 | HCAR2 | Q8TDS4 | DB00627 | Niacin | yes | agonist | small molecule | approved, investigational, nutraceutical | A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has pellagra-curative, vasodilating, and antilipemic properties. [PubChem] |
| Search | 799 | CALCR | P30988 | DB00017 | Salmon Calcitonin | unknown | agonist | biotech | approved, investigational | Synthetic peptide, 32 residues long formulated as a nasal spray. |
| Search | 6344 | SCTR | P47872 | DB00021 | Secretin | yes | agonist | biotech | approved, investigational | This drug is the synthetic form of natural secretin. It is prepared using solid phase peptide synthesis. Secretin is a peptide hormone produced in the S cells of the duodenum. Its main effect is to regulate the pH of the small intestineÌÎÌ__ÌÎÌ__ÌÎå«ÌÎ̦s contents through the control of gastric acid secretion and buffering with bicarbonate. It was the first hormone to be discovered. |
| Search | 3643 | INSR | P06213 | DB00030 | Insulin Human | yes | agonist | biotech | approved, investigational | \\Insulin human is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use. |
| Search | 3480 | IGF1R | P08069 | DB00030 | Insulin Human | unknown | biotech | approved, investigational | \\Insulin human is a 51 residue peptide hormone, composed of two amino acid chains covalently linked by disulfide bonds. The structure is identical to native human insulin. Recombinant insulin is synthesized by recombinant DNA techncology. Inserting the human insulin gene into the Escherichia coli bacteria or Saccharomyces cerevisiae produces insulin for human use. | |
| Search | 3973 | LHCGR | P22888 | DB00050 | Cetrorelix | unknown | small molecule | approved, investigational | Cetrorelix is a man-made hormone that blocks the effects of Gonadotropin Releasing Hormone (GnRH). GnRH controls another hormone that is called luteinizing hormone (LH), which is the hormone that starts ovulation during the menstrual cycle. When undergoing hormone treatment sometimes premature ovulation can occur, leading to eggs that are not ready for fertilization to be released. Cetrorelix does not allow the premature release of these eggs to occur. | |
| Search | 6751 | SSTR1 | P30872 | DB00104 | Octreotide | yes | small molecule | approved, investigational | Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. | |
| Search | 6755 | SSTR5 | P35346 | DB00104 | Octreotide | yes | small molecule | approved, investigational | Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. | |
| Search | 6752 | SSTR2 | P30874 | DB00104 | Octreotide | yes | binder | small molecule | approved, investigational | Octreotide is the acetate salt of a cyclic octapeptide. It is a long-acting octapeptide with pharmacologic properties mimicking those of the natural hormone somatostatin. |
| Search | 4988 | OPRM1 | P35372 | DB00193 | Tramadol | yes | agonist | small molecule | approved, investigational | \\A narcotic analgesic proposed for moderate to severe pain. It may be habituating. [PubChem] Tramadol is also prepared as a variable release capsules, marketed under the brand name ConZip. For example, a 150 mg capsule will contain 37.5 mg of the immediate release form and 112.5 mg of the extended release form. |
| Search | 4986 | OPRK1 | P41145 | DB00193 | Tramadol | unknown | agonist | small molecule | approved, investigational | \\A narcotic analgesic proposed for moderate to severe pain. It may be habituating. [PubChem] Tramadol is also prepared as a variable release capsules, marketed under the brand name ConZip. For example, a 150 mg capsule will contain 37.5 mg of the immediate release form and 112.5 mg of the extended release form. |
Click here to search for all sets and networks involving any of the 48 genes of this set.
| Search | Entrez Gene ID | HGNC Approved Symbol | UniProtKB Acc | Human Ensembl Gene ID | Panel GO term ID | Panel GO term name | GO term ID | GO term name |
|---|---|---|---|---|---|---|---|---|
| Search | 2778 | GNAS | O95467 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 409 | ARRB2 | P32121 | ENSG00000141480 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 2778 | GNAS | P63092 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 1742 | DLG4 | P78352 | ENSG00000132535 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 2778 | GNAS | P84996 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 2778 | GNAS | Q5JWF2 | ENSG00000087460 | GO:0050780 | dopamine receptor binding | GO:0031748 | D1 dopamine receptor binding |
| Search | 2778 | GNAS | O95467 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 111 | ADCY5 | O95622 | ENSG00000173175 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 1816 | DRD5 | P21918 | ENSG00000169676 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 3274 | HRH2 | P25021 | ENSG00000113749 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 4988 | OPRM1 | P35372 | ENSG00000112038 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 54331 | GNG2 | P59768 | ENSG00000186469 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 2778 | GNAS | P63092 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 2778 | GNAS | P84996 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 2778 | GNAS | Q5JWF2 | ENSG00000087460 | GO:0007212 | dopamine receptor signaling pathway | GO:0007191 | adenylate cyclase-activating dopamine receptor signaling pathway |
| Search | 111 | ADCY5 | O95622 | ENSG00000173175 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0007195 | adenylate cyclase-inhibiting dopamine receptor signaling pathway |
| Search | 2775 | GNAO1 | P09471 | ENSG00000087258 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0007212 | dopamine receptor signaling pathway | GO:0007212 | dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 1816 | DRD5 | P21918 | ENSG00000169676 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 3274 | HRH2 | P25021 | ENSG00000113749 | GO:0007212 | dopamine receptor signaling pathway | GO:0060158 | phospholipase C-activating dopamine receptor signaling pathway |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007212 | dopamine receptor signaling pathway | GO:0060159 | regulation of dopamine receptor signaling pathway |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0007212 | dopamine receptor signaling pathway | GO:0060160 | negative regulation of dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0060160 | negative regulation of dopamine receptor signaling pathway |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0007212 | dopamine receptor signaling pathway | GO:0060161 | positive regulation of dopamine receptor signaling pathway |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007212 | dopamine receptor signaling pathway | GO:0060161 | positive regulation of dopamine receptor signaling pathway |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0005329 | dopamine transmembrane transporter activity | GO:0005329 | dopamine transmembrane transporter activity |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0005329 | dopamine transmembrane transporter activity | GO:0005330 | dopamine:sodium symporter activity |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1392 | CRH | P06850 | ENSG00000147571 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1816 | DRD5 | P21918 | ENSG00000169676 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 3274 | HRH2 | P25021 | ENSG00000113749 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0001963 | synaptic transmission, dopaminergic | GO:0001963 | synaptic transmission, dopaminergic |
| Search | 409 | ARRB2 | P32121 | ENSG00000141480 | GO:0001963 | synaptic transmission, dopaminergic | GO:0032226 | positive regulation of synaptic transmission, dopaminergic |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0001963 | synaptic transmission, dopaminergic | GO:0032226 | positive regulation of synaptic transmission, dopaminergic |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051585 | negative regulation of dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001963 | synaptic transmission, dopaminergic | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 11255 | HRH3 | Q9Y5N1 | ENSG00000101180 | GO:0001505 | regulation of neurotransmitter levels | GO:0001505 | regulation of neurotransmitter levels |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0001956 | positive regulation of neurotransmitter secretion |
| Search | 6853 | SYN1 | P17600 | ENSG00000008056 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 4128 | MAOA | P21397 | ENSG00000189221 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 2914 | GRM4 | Q14833 | ENSG00000124493 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 11255 | HRH3 | Q9Y5N1 | ENSG00000101180 | GO:0001505 | regulation of neurotransmitter levels | GO:0007269 | neurotransmitter secretion |
| Search | 4128 | MAOA | P21397 | ENSG00000189221 | GO:0001505 | regulation of neurotransmitter levels | GO:0042135 | neurotransmitter catabolic process |
| Search | 1312 | COMT | P21964 | ENSG00000093010 | GO:0001505 | regulation of neurotransmitter levels | GO:0042135 | neurotransmitter catabolic process |
| Search | 4128 | MAOA | P21397 | ENSG00000189221 | GO:0001505 | regulation of neurotransmitter levels | GO:0042136 | neurotransmitter biosynthetic process |
| Search | 1312 | COMT | P21964 | ENSG00000093010 | GO:0001505 | regulation of neurotransmitter levels | GO:0042136 | neurotransmitter biosynthetic process |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0001505 | regulation of neurotransmitter levels | GO:0042136 | neurotransmitter biosynthetic process |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 4803 | NGF | P01138 | ENSG00000134259 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 6853 | SYN1 | P17600 | ENSG00000008056 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 815 | CAMK2A | Q9UQM7 | ENSG00000070808 | GO:0001505 | regulation of neurotransmitter levels | GO:0046928 | regulation of neurotransmitter secretion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:0051582 | positive regulation of neurotransmitter uptake |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 6531 | SLC6A3 | Q01959 | ENSG00000142319 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0001505 | regulation of neurotransmitter levels | GO:0051583 | dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001505 | regulation of neurotransmitter levels | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 1814 | DRD3 | P35462 | ENSG00000151577 | GO:0001505 | regulation of neurotransmitter levels | GO:0051584 | regulation of dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051585 | negative regulation of dopamine uptake involved in synaptic transmission |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0001505 | regulation of neurotransmitter levels | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 1815 | DRD4 | P21917 | ENSG00000069696 | GO:0001505 | regulation of neurotransmitter levels | GO:0051586 | positive regulation of dopamine uptake involved in synaptic transmission |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051612 | negative regulation of serotonin uptake |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0001505 | regulation of neurotransmitter levels | GO:0051622 | negative regulation of norepinephrine uptake |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0001505 | regulation of neurotransmitter levels | GO:1904049 | negative regulation of spontaneous neurotransmitter secretion |
| Search | 6853 | SYN1 | P17600 | ENSG00000008056 | GO:0001505 | regulation of neurotransmitter levels | GO:2000300 | regulation of synaptic vesicle exocytosis |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0001505 | regulation of neurotransmitter levels | GO:2000300 | regulation of synaptic vesicle exocytosis |
| Search | 10636 | RGS14 | O43566 | ENSG00000169220 | GO:0048167 | regulation of synaptic plasticity | GO:0031914 | negative regulation of synaptic plasticity |
| Search | 9610 | RIN1 | Q13671 | ENSG00000174791 | GO:0048167 | regulation of synaptic plasticity | GO:0031914 | negative regulation of synaptic plasticity |
| Search | 10755 | GIPC1 | O14908 | ENSG00000123159 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 3274 | HRH2 | P25021 | ENSG00000113749 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 134 | ADORA1 | P30542 | ENSG00000163485 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 7532 | YWHAG | P61981 | ENSG00000170027 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 7533 | YWHAH | Q04917 | ENSG00000128245 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 2904 | GRIN2B | Q13224 | ENSG00000273079 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 1979 | EIF4EBP2 | Q13542 | ENSG00000148730 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 9463 | PICK1 | Q9NRD5 | ENSG00000100151 | GO:0048167 | regulation of synaptic plasticity | GO:0048167 | regulation of synaptic plasticity |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0048167 | regulation of synaptic plasticity | GO:0048168 | regulation of neuronal synaptic plasticity |
| Search | 1627 | DBN1 | Q16643 | ENSG00000113758 | GO:0048167 | regulation of synaptic plasticity | GO:0048168 | regulation of neuronal synaptic plasticity |
| Search | 815 | CAMK2A | Q9UQM7 | ENSG00000070808 | GO:0048167 | regulation of synaptic plasticity | GO:0048168 | regulation of neuronal synaptic plasticity |
| Search | 183 | AGT | P01019 | ENSG00000135744 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 3265 | HRAS | P01112 | ENSG00000174775 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 1742 | DLG4 | P78352 | ENSG00000132535 | GO:0048167 | regulation of synaptic plasticity | GO:0048169 | regulation of long-term neuronal synaptic plasticity |
| Search | 3815 | KIT | P10721 | ENSG00000157404 | GO:0048167 | regulation of synaptic plasticity | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048170 | positive regulation of long-term neuronal synaptic plasticity |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0048167 | regulation of synaptic plasticity | GO:0048172 | regulation of short-term neuronal synaptic plasticity |
| Search | 10636 | RGS14 | O43566 | ENSG00000169220 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 1392 | CRH | P06850 | ENSG00000147571 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 2695 | GIP | P09681 | ENSG00000159224 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 5594 | MAPK1 | P28482 | ENSG00000100030 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 5728 | PTEN | P60484 | ENSG00000171862 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 5590 | PRKCZ | Q05513 | ENSG00000067606 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 2904 | GRIN2B | Q13224 | ENSG00000273079 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 1395 | CRHR2 | Q13324 | ENSG00000106113 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 4915 | NTRK2 | Q16620 | ENSG00000148053 | GO:0048167 | regulation of synaptic plasticity | GO:0060291 | long-term synaptic potentiation |
| Search | 1816 | DRD5 | P21918 | ENSG00000169676 | GO:0048167 | regulation of synaptic plasticity | GO:0060292 | long term synaptic depression |
| Search | 2890 | GRIA1 | P42261 | ENSG00000155511 | GO:0048167 | regulation of synaptic plasticity | GO:0060292 | long term synaptic depression |
| Search | 5728 | PTEN | P60484 | ENSG00000171862 | GO:0048167 | regulation of synaptic plasticity | GO:0060292 | long term synaptic depression |
| Search | 9463 | PICK1 | Q9NRD5 | ENSG00000100151 | GO:0048167 | regulation of synaptic plasticity | GO:0060292 | long term synaptic depression |
| Search | 1813 | DRD2 | P14416 | ENSG00000149295 | GO:0048167 | regulation of synaptic plasticity | GO:1900273 | positive regulation of long-term synaptic potentiation |
| Search | 134 | ADORA1 | P30542 | ENSG00000163485 | GO:0048167 | regulation of synaptic plasticity | GO:1900453 | negative regulation of long term synaptic depression |
Click here to search for all sets and networks involving any of the 84 genes of this set.
| Search | Entrez Gene ID | HGNC Approved Symbol | UniProtKB Acc | Human Ensembl Gene ID | Panel GO term ID | Panel GO term name | GO term ID | GO term name |
|---|---|---|---|---|---|---|---|---|
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006119 | oxidative phosphorylation | GO:0002082 | regulation of oxidative phosphorylation |
| Search | 4436 | MSH2 | P43246 | ENSG00000095002 | GO:0006119 | oxidative phosphorylation | GO:0006119 | oxidative phosphorylation |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0006119 | oxidative phosphorylation | GO:0006120 | mitochondrial electron transport, NADH to ubiquinone |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0006119 | oxidative phosphorylation | GO:0042775 | mitochondrial ATP synthesis coupled electron transport |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0006119 | oxidative phosphorylation | GO:1902957 | negative regulation of mitochondrial electron transport, NADH to ubiquinone |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0006119 | oxidative phosphorylation | GO:1902958 | positive regulation of mitochondrial electron transport, NADH to ubiquinone |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006119 | oxidative phosphorylation | GO:1902958 | positive regulation of mitochondrial electron transport, NADH to ubiquinone |
| Search | 7415 | VCP | P55072 | ENSG00000165280 | GO:0006119 | oxidative phosphorylation | GO:1903862 | positive regulation of oxidative phosphorylation |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0000422 | mitochondrion degradation | GO:0000422 | mitophagy |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0000422 | mitochondrion degradation | GO:0000422 | mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0000422 | mitochondrion degradation | GO:0000422 | mitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5539 | PPY | P01298 | ENSG00000108849 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 797 | CALCB | P10092 | ENSG00000175868 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5290 | PIK3CA | P42336 | ENSG00000121879 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 27198 | HCAR1 | Q9BXC0 | ENSG00000196917 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 22985 | ACIN1 | Q9UKV3 | ENSG00000100813 | GO:0000422 | mitochondrion degradation | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0000422 | mitochondrion degradation | GO:1901525 | negative regulation of macromitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0000422 | mitochondrion degradation | GO:1903146 | regulation of mitophagy |
| Search | 55294 | FBXW7 | Q969H0 | ENSG00000109670 | GO:0000422 | mitochondrion degradation | GO:1903146 | regulation of mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0000422 | mitochondrion degradation | GO:1903146 | regulation of mitophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0000422 | mitochondrion degradation | GO:1903147 | negative regulation of mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0000422 | mitochondrion degradation | GO:1903147 | negative regulation of mitophagy |
| Search | 3091 | HIF1A | Q16665 | ENSG00000100644 | GO:0000422 | mitochondrion degradation | GO:1903599 | positive regulation of mitophagy |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0000422 | mitochondrion degradation | GO:1903599 | positive regulation of mitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0000266 | mitochondrial fission |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0000422 | mitophagy |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0007005 | mitochondrion organization | GO:0000422 | mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:0000422 | mitophagy |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 3725 | JUN | P05412 | ENSG00000177606 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 596 | BCL2 | P10415 | ENSG00000171791 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 2810 | SFN | P31947 | ENSG00000175793 | GO:0007005 | mitochondrion organization | GO:0001836 | release of cytochrome c from mitochondria |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:0007005 | mitochondrion organization |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0007005 | mitochondrion organization | GO:0007006 | mitochondrial membrane organization |
| Search | 596 | BCL2 | P10415 | ENSG00000171791 | GO:0007005 | mitochondrion organization | GO:0008637 | apoptotic mitochondrial changes |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0007005 | mitochondrion organization | GO:0008637 | apoptotic mitochondrial changes |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0010636 | positive regulation of mitochondrial fusion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0010637 | negative regulation of mitochondrial fusion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0010821 | regulation of mitochondrion organization |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0007005 | mitochondrion organization | GO:0010821 | regulation of mitochondrion organization |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:0010821 | regulation of mitochondrion organization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0035794 | positive regulation of mitochondrial membrane permeability |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0043504 | mitochondrial DNA repair |
| Search | 3320 | HSP90AA1 | P07900 | ENSG00000080824 | GO:0007005 | mitochondrion organization | GO:0045040 | protein import into mitochondrial outer membrane |
| Search | 3308 | HSPA4 | P34932 | ENSG00000170606 | GO:0007005 | mitochondrion organization | GO:0045040 | protein import into mitochondrial outer membrane |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0046902 | regulation of mitochondrial membrane permeability |
| Search | 596 | BCL2 | P10415 | ENSG00000171791 | GO:0007005 | mitochondrion organization | GO:0046902 | regulation of mitochondrial membrane permeability |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0007005 | mitochondrion organization | GO:0046902 | regulation of mitochondrial membrane permeability |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:0048312 | intracellular distribution of mitochondria |
| Search | 708 | C1QBP | Q07021 | ENSG00000108561 | GO:0007005 | mitochondrion organization | GO:0070131 | positive regulation of mitochondrial translation |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:0090140 | regulation of mitochondrial fission |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0090141 | positive regulation of mitochondrial fission |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:0090141 | positive regulation of mitochondrial fission |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:0090200 | positive regulation of release of cytochrome c from mitochondria |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:0090200 | positive regulation of release of cytochrome c from mitochondria |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 4000 | LMNA | P02545 | ENSG00000160789 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 3479 | IGF1 | P05019 | ENSG00000017427 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 409 | ARRB2 | P32121 | ENSG00000141480 | GO:0007005 | mitochondrion organization | GO:0090201 | negative regulation of release of cytochrome c from mitochondria |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:0090258 | negative regulation of mitochondrial fission |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5539 | PPY | P01298 | ENSG00000108849 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 797 | CALCB | P10092 | ENSG00000175868 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5290 | PIK3CA | P42336 | ENSG00000121879 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 27198 | HCAR1 | Q9BXC0 | ENSG00000196917 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 22985 | ACIN1 | Q9UKV3 | ENSG00000100813 | GO:0007005 | mitochondrion organization | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 596 | BCL2 | P10415 | ENSG00000171791 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 10971 | YWHAQ | P27348 | ENSG00000134308 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 7529 | YWHAB | P31946 | ENSG00000166913 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 2810 | SFN | P31947 | ENSG00000175793 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 5599 | MAPK8 | P45983 | ENSG00000107643 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 7532 | YWHAG | P61981 | ENSG00000170027 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 7531 | YWHAE | P62258 | ENSG00000108953 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 7534 | YWHAZ | P63104 | ENSG00000164924 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 7533 | YWHAH | Q04917 | ENSG00000128245 | GO:0007005 | mitochondrion organization | GO:1900740 | positive regulation of protein insertion into mitochondrial membrane involved in apoptotic signaling pathway |
| Search | 2932 | GSK3B | P49841 | ENSG00000082701 | GO:0007005 | mitochondrion organization | GO:1901030 | positive regulation of mitochondrial outer membrane permeabilization involved in apoptotic signaling pathway |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:1901525 | negative regulation of macromitophagy |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0007005 | mitochondrion organization | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process |
| Search | 815 | CAMK2A | Q9UQM7 | ENSG00000070808 | GO:0007005 | mitochondrion organization | GO:1902108 | regulation of mitochondrial membrane permeability involved in apoptotic process |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:1903146 | regulation of mitophagy |
| Search | 55294 | FBXW7 | Q969H0 | ENSG00000109670 | GO:0007005 | mitochondrion organization | GO:1903146 | regulation of mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:1903146 | regulation of mitophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0007005 | mitochondrion organization | GO:1903147 | negative regulation of mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:1903147 | negative regulation of mitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0007005 | mitochondrion organization | GO:1903214 | regulation of protein targeting to mitochondrion |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:1903214 | regulation of protein targeting to mitochondrion |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:1903215 | negative regulation of protein targeting to mitochondrion |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0007005 | mitochondrion organization | GO:1903217 | negative regulation of protein processing involved in protein targeting to mitochondrion |
| Search | 3091 | HIF1A | Q16665 | ENSG00000100644 | GO:0007005 | mitochondrion organization | GO:1903599 | positive regulation of mitophagy |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0007005 | mitochondrion organization | GO:1903599 | positive regulation of mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:1903852 | positive regulation of cristae formation |
| Search | 3176 | HNMT | P50135 | ENSG00000150540 | GO:0007005 | mitochondrion organization | GO:1903955 | positive regulation of protein targeting to mitochondrion |
| Search | 55294 | FBXW7 | Q969H0 | ENSG00000109670 | GO:0007005 | mitochondrion organization | GO:1903955 | positive regulation of protein targeting to mitochondrion |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0007005 | mitochondrion organization | GO:1903955 | positive regulation of protein targeting to mitochondrion |
| Search | 10316 | NMUR1 | Q9HB89 | ENSG00000171596 | GO:0007005 | mitochondrion organization | GO:1903955 | positive regulation of protein targeting to mitochondrion |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0000422 | mitophagy |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0006914 | autophagy | GO:0000422 | mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:0000422 | mitophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 6794 | STK11 | Q15831 | ENSG00000118046 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:0006914 | autophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 596 | BCL2 | P10415 | ENSG00000171791 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 4137 | MAPT | P10636 | ENSG00000186868 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 27 | ABL2 | P42684 | ENSG00000143322 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 10670 | RRAGA | Q7L523 | ENSG00000155876 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 64121 | RRAGC | Q9HB90 | ENSG00000116954 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 58528 | RRAGD | Q9NQL2 | ENSG00000025039 | GO:0006914 | autophagy | GO:0010506 | regulation of autophagy |
| Search | 596 | BCL2 | P10415 | ENSG00000171791 | GO:0006914 | autophagy | GO:0010507 | negative regulation of autophagy |
| Search | 207 | AKT1 | P31749 | ENSG00000142208 | GO:0006914 | autophagy | GO:0010507 | negative regulation of autophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:0010507 | negative regulation of autophagy |
| Search | 10670 | RRAGA | Q7L523 | ENSG00000155876 | GO:0006914 | autophagy | GO:0010507 | negative regulation of autophagy |
| Search | 3091 | HIF1A | Q16665 | ENSG00000100644 | GO:0006914 | autophagy | GO:0010508 | positive regulation of autophagy |
| Search | 120892 | LRRK2 | Q5S007 | ENSG00000188906 | GO:0006914 | autophagy | GO:0010508 | positive regulation of autophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 6009 | RHEB | Q15382 | ENSG00000106615 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 10670 | RRAGA | Q7L523 | ENSG00000155876 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 57521 | RPTOR | Q8N122 | ENSG00000141564 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 64223 | MLST8 | Q9BVC4 | ENSG00000167965 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 64121 | RRAGC | Q9HB90 | ENSG00000116954 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 58528 | RRAGD | Q9NQL2 | ENSG00000025039 | GO:0006914 | autophagy | GO:0016236 | macroautophagy |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0006914 | autophagy | GO:0016239 | positive regulation of macroautophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:0016239 | positive regulation of macroautophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:0016242 | negative regulation of macroautophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:0016242 | negative regulation of macroautophagy |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5539 | PPY | P01298 | ENSG00000108849 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 797 | CALCB | P10092 | ENSG00000175868 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 5290 | PIK3CA | P42336 | ENSG00000121879 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 8878 | SQSTM1 | Q13501 | ENSG00000161011 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 27198 | HCAR1 | Q9BXC0 | ENSG00000196917 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 22985 | ACIN1 | Q9UKV3 | ENSG00000100813 | GO:0006914 | autophagy | GO:0098779 | activation of mitophagy in response to mitochondrial depolarization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0006914 | autophagy | GO:1901525 | negative regulation of macromitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:1902902 | negative regulation of autophagosome assembly |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0006914 | autophagy | GO:1903146 | regulation of mitophagy |
| Search | 55294 | FBXW7 | Q969H0 | ENSG00000109670 | GO:0006914 | autophagy | GO:1903146 | regulation of mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:1903146 | regulation of mitophagy |
| Search | 2475 | MTOR | P42345 | ENSG00000198793 | GO:0006914 | autophagy | GO:1903147 | negative regulation of mitophagy |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0006914 | autophagy | GO:1903147 | negative regulation of mitophagy |
| Search | 3091 | HIF1A | Q16665 | ENSG00000100644 | GO:0006914 | autophagy | GO:1903599 | positive regulation of mitophagy |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0006914 | autophagy | GO:1903599 | positive regulation of mitophagy |
| Search | 3320 | HSP90AA1 | P07900 | ENSG00000080824 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3326 | HSP90AB1 | P08238 | ENSG00000096384 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 60 | ACTB | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 60 | ACTG1 | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 10376 | TUBA1B | P68363 | ENSG00000123416 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 7846 | TUBA1A | Q71U36 | ENSG00000167552 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 81027 | TUBB1 | Q9H4B7 | ENSG00000101162 | GO:0006457 | protein folding | GO:0006457 | protein folding |
| Search | 3320 | HSP90AA1 | P07900 | ENSG00000080824 | GO:0006457 | protein folding | GO:0042026 | protein refolding |
| Search | 60 | ACTB | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 60 | ACTG1 | P60709 | ENSG00000075624 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 10376 | TUBA1B | P68363 | ENSG00000123416 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 7846 | TUBA1A | Q71U36 | ENSG00000167552 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 81027 | TUBB1 | Q9H4B7 | ENSG00000101162 | GO:0006457 | protein folding | GO:0051084 | 'de novo' posttranslational protein folding |
| Search | 6714 | SRC | P12931 | ENSG00000197122 | GO:0031648 | protein destabilization | GO:0031648 | protein destabilization |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0031648 | protein destabilization | GO:0031648 | protein destabilization |
| Search | 5591 | PRKDC | P78527 | ENSG00000253729 | GO:0031648 | protein destabilization | GO:0031648 | protein destabilization |
| Search | 7157 | TP53 | P04637 | ENSG00000141510 | GO:0070997 | neuron death | GO:0043523 | regulation of neuron apoptotic process |
| Search | 4908 | NTF3 | P20783 | ENSG00000185652 | GO:0070997 | neuron death | GO:0043523 | regulation of neuron apoptotic process |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0070997 | neuron death | GO:0043523 | regulation of neuron apoptotic process |
| Search | 2914 | GRM4 | Q14833 | ENSG00000124493 | GO:0070997 | neuron death | GO:0043523 | regulation of neuron apoptotic process |
| Search | 84335 | AKT1S1 | Q96B36 | ENSG00000204673 | GO:0070997 | neuron death | GO:0043523 | regulation of neuron apoptotic process |
| Search | 11315 | PARK7 | Q99497 | ENSG00000116288 | GO:0070997 | neuron death | GO:0043523 | regulation of neuron apoptotic process |
| Search | 65018 | PINK1 | Q9BXM7 | ENSG00000158828 | GO:0070997 | neuron death | GO:0043523 | regulation of neuron apoptotic process |
| Search | 5071 | PARK2 | O60260 | ENSG00000185345 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 183 | AGT | P01019 | ENSG00000135744 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 3265 | HRAS | P01112 | ENSG00000174775 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 4803 | NGF | P01138 | ENSG00000134259 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 4914 | NTRK1 | P04629 | ENSG00000198400 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 3725 | JUN | P05412 | ENSG00000177606 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 4804 | NGFR | P08138 | ENSG00000064300 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 3326 | HSP90AB1 | P08238 | ENSG00000096384 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 6343 | SCT | P09683 | ENSG00000070031 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 596 | BCL2 | P10415 | ENSG00000171791 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 4908 | NTF3 | P20783 | ENSG00000185652 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 627 | BDNF | P23560 | ENSG00000176697 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 6622 | SNCA | P37840 | ENSG00000145335 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 5290 | PIK3CA | P42336 | ENSG00000121879 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 3064 | HTT | P42858 | ENSG00000197386 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 4436 | MSH2 | P43246 | ENSG00000095002 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 4544 | MTNR1B | P49286 | ENSG00000134640 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 4915 | NTRK2 | Q16620 | ENSG00000148053 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
| Search | 3091 | HIF1A | Q16665 | ENSG00000100644 | GO:0070997 | neuron death | GO:0043524 | negative regulation of neuron apoptotic process |
Click here to search for all sets and networks involving any of the 6 genes of this set.
| Search | Entrez Gene ID | HGNC symbol | Associated diseases | HPO ID |
|---|---|---|---|---|
| Search | 6531 | SLC6A3 | PARKINSONISM-DYSTONIA, INFANTILE (OMIM:613135 | HP:0001300 |
| Search | 4137 | MAPT | PICK DISEASE OF BRAIN (OMIM:172700, SUPRANUCLEAR PALSY, PROGRESSIVE, 1 (OMIM:601104, FRONTOTEMPORAL DEMENTIA (OMIM:600274, PARKINSON-DEMENTIA SYNDROMESUPRANUCLEAR ... (OMIM:260540 | HP:0001300 |
| Search | 5071 | PARK2 | PARKINSON DISEASE 2, AUTOSOMAL RECESSIVE... (OMIM:600116, LUNG CANCERALVEOLAR CELL CARCINOMA, INCL... (OMIM:211980, OVARIAN CANCEROVARIAN CANCER, EPITHELIAL... (OMIM:167000 | HP:0001300 |
| Search | 6622 | SNCA | PARKINSON DISEASE 1, AUTOSOMAL DOMINANT (OMIM:168601, PARKINSON DISEASE 4, AUTOSOMAL DOMINANT ... (OMIM:605543, DEMENTIA, LEWY BODY (OMIM:127750 | HP:0001300 |
| Search | 351 | APP | CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED (OMIM:605714, ALZHEIMER DISEASE (OMIM:104300 | HP:0001300 |
| Search | 65018 | PINK1 | PARKINSON DISEASE 6, AUTOSOMAL RECESSIVE... (OMIM:605909 | HP:0001300 |
| Search | 351 | APP | CEREBRAL AMYLOID ANGIOPATHY, APP-RELATED (OMIM:605714, ALZHEIMER DISEASE (OMIM:104300 | HP:0002511 |
Click here to search for all sets and networks involving any of the 2 genes of this set.
| Search | Entrez ID | HGNC Symbol | Ensembl Gene ID | Uniprot Accession | Reference | PMID |
|---|---|---|---|---|---|---|
| Search | 1981 | EIF4G1 | ENSG00000114867 | Q04637 | Chartier-Harlin et al. Am J Hum Genet 2011 89:398-406 | 21907011 |
| Search | 4157 | MC1R | ENSG00000258839 | Q01726 | Gao Ann Neurol 2009 65:76-82 | 19194882 |
Click here to search for all sets and networks involving any of the 1 genes of this set.
| Search | Entrez ID | HGNC Symbol | Ensembl Gene ID | Uniprot Accession | Reference | PMID |
|---|---|---|---|---|---|---|
| Search | 4137 | MAPT | ENSG00000186868 | P10636 | Simon-Sanchez et al. Nat Genet 2009 41:1308-1312 | 19915575 |
Click here to search for all sets and networks involving any of the 5 genes of this set.
| Search | Entrez ID | HGNC Symbol | Ensembl Gene ID | Uniprot Accession | Reference | PMID |
|---|---|---|---|---|---|---|
| Search | 6622 | SNCA | ENSG00000145335 | P37840 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |
| Search | 5071 | PARK2 | ENSG00000185345 | O60260 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |
| Search | 65018 | PINK1 | ENSG00000158828 | Q9BXM7 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |
| Search | 11315 | PARK7 | ENSG00000116288 | Q99497 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |
| Search | 120892 | LRRK2 | ENSG00000188906 | Q5S007 | Corti et al. Physiol Rev 2011 91:1161-1218 | 22013209 |